Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Comment by Babaxteron Feb 04, 2021 7:07pm
107 Views
Post# 32479920

RE:Corporate Update/Share Price

RE:Corporate Update/Share Price

Ingiboy wrote: Two days to go in the &quot;first week of February&quot;.<br /> <br /> Nice to see the share price begin to rise in anticipation of the Corporate Update. &nbsp;I have to admit that the series of tweets this past week have most likely helped attract some investors. We now have a decent launch price for this Corporate Update.<br /> Lots of chatter on share price and exit price. &nbsp;I think that has all to do with a persons average share price. &nbsp;There have been many that have bought cheap shares over the past couple of years and there many of us that bought shares over $1.00. &nbsp;We dumped on Babaxter when he/she posted their share forecast but it could be a reasonable template for the shareprice is going:<br /> <br /> <p style="box-sizing: inherit; outline: 0px; margin: 5px 0px 7px; padding: 0px; font-size: 13.199999809265137px; line-height: 21px; text-rendering: optimizeLegibility; caret-color: rgb(10, 10, 10); color: rgb(10, 10, 10); font-family: Arial, Helvetica, sans-serif;"> &quot;Jan - feb 2021 will be around $0.675 to $1 after the corporate news release in first week of February with details about plans for this year&nbsp;<br style="box-sizing: inherit; outline: 0px;" /> <br style="box-sizing: inherit; outline: 0px;" /> March - April between $1-$2 &nbsp;up to dermal injector approval, tests, marketing&nbsp;<br style="box-sizing: inherit; outline: 0px;" /> <br style="box-sizing: inherit; outline: 0px;" /> May and June around $2 - $3 depending upon Japan products but just the injector makes Replicel market value only $80 - $120 million at this price&nbsp;<br style="box-sizing: inherit; outline: 0px;" /> <br style="box-sizing: inherit; outline: 0px;" /> July/Aug/Sept/Oct if it&#39;s showing that market launch or approval is good then over $3.&nbsp;</p> <p style="box-sizing: inherit; outline: 0px; margin: 5px 0px 7px; padding: 0px; font-size: 13.199999809265137px; line-height: 21px; text-rendering: optimizeLegibility; caret-color: rgb(10, 10, 10); color: rgb(10, 10, 10); font-family: Arial, Helvetica, sans-serif;"> Nov/Dec could be up to $5 if dermal injector is launched and definitely if other products in line. &quot;<br /> <br /> Regarding exit price, I am going to hang around for that $5.00 share price !!!</p> <div> &nbsp;</div> <br /> <br />
<br /> <br />


All I will say Is that there's no way Mainpointe was going to buy at 67 cents if they weren't in it to make their money back. No way they go in with this one if they weren't planning to 10X the investment and thats $6.75. Waste of time with too much risk if it's only $3, $4, $5 or whatever. No way they will be sitting on their hands, they are going to get there as fast as it takes to get an FDA. They took forever to sign it's because they did there DD and they found who the customer is going to be. I wouldn't buy it if I didn't know who I'd sell it to. 

IDK why there is not more posting on Reddit or no one is going to know what Replicel is. Need to gamespot this.  Deleting my account now  as$ s

<< Previous
Bullboard Posts
Next >>